Financial Counselors Inc. Has $24.07 Million Holdings in Danaher Corporation (NYSE:DHR)

Financial Counselors Inc. boosted its position in Danaher Corporation (NYSE:DHR - Free Report) by 3.9% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 117,434 shares of the conglomerate's stock after purchasing an additional 4,378 shares during the period. Financial Counselors Inc.'s holdings in Danaher were worth $24,074,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in DHR. Heck Capital Advisors LLC acquired a new stake in shares of Danaher in the fourth quarter valued at $27,000. GHP Investment Advisors Inc. raised its position in Danaher by 396.0% in the first quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate's stock worth $25,000 after acquiring an additional 99 shares in the last quarter. Sierra Ocean LLC lifted its holdings in Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate's stock valued at $29,000 after acquiring an additional 76 shares during the last quarter. Hurley Capital LLC bought a new position in shares of Danaher during the 4th quarter valued at about $34,000. Finally, Rialto Wealth Management LLC bought a new position in shares of Danaher during the 4th quarter valued at about $34,000. 79.05% of the stock is owned by institutional investors.

Danaher Stock Down 1.8%

DHR traded down $3.60 on Monday, reaching $199.60. 2,388,352 shares of the company traded hands, compared to its average volume of 3,495,257. The company has a market cap of $142.85 billion, a price-to-earnings ratio of 38.76, a PEG ratio of 2.85 and a beta of 0.77. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.43 and a quick ratio of 1.05. The stock's 50 day moving average price is $195.63 and its 200-day moving average price is $207.10. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $281.70.

Danaher (NYSE:DHR - Get Free Report) last posted its quarterly earnings results on Tuesday, April 22nd. The conglomerate reported $1.88 EPS for the quarter, beating the consensus estimate of $1.62 by $0.26. Danaher had a net margin of 15.81% and a return on equity of 10.80%. The business had revenue of $5.74 billion for the quarter, compared to analysts' expectations of $5.58 billion. On average, sell-side analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a yield of 0.64%. Danaher's dividend payout ratio (DPR) is currently 24.85%.

Insider Activity

In other news, EVP Christopher Paul Riley sold 15,805 shares of Danaher stock in a transaction dated Wednesday, April 30th. The stock was sold at an average price of $198.00, for a total transaction of $3,129,390.00. Following the completion of the sale, the executive vice president directly owned 15,179 shares in the company, valued at $3,005,442. The trade was a 51.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Chairman Steven M. Rales sold 1,250,000 shares of the stock in a transaction that occurred on Monday, May 12th. The stock was sold at an average price of $196.74, for a total value of $245,925,000.00. Following the completion of the transaction, the chairman owned 3,105,808 shares in the company, valued at $611,036,665.92. This represents a 28.70% decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 11.20% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts recently commented on DHR shares. Wolfe Research dropped their target price on shares of Danaher from $275.00 to $220.00 and set an "outperform" rating on the stock in a report on Monday, April 7th. HSBC dropped their price target on Danaher from $270.00 to $240.00 in a report on Friday, April 25th. The Goldman Sachs Group reduced their price objective on Danaher from $260.00 to $240.00 and set a "neutral" rating for the company in a research note on Wednesday, April 23rd. Wall Street Zen raised Danaher from a "hold" rating to a "buy" rating in a research report on Friday, June 27th. Finally, JPMorgan Chase & Co. reduced their target price on Danaher from $280.00 to $260.00 and set an "overweight" rating for the company in a report on Tuesday, April 22nd. Four research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus target price of $248.61.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.